Robbie Marcus
Stock Analyst at JP Morgan
(4.33)
# 463
Out of 4,412 analysts
88
Total ratings
59.09%
Success rate
12.66%
Average return
Main Sectors:
Top Industries:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNMD CONMED | Maintains: Overweight | $115 → $75 | $65.78 | +14.02% | 4 | Apr 25, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $72 → $82 | $73.17 | +12.07% | 4 | Apr 25, 2024 | |
| COO The Cooper Companies | Upgrades: Overweight | $100 → $120 | $88.84 | +35.07% | 3 | Mar 13, 2024 | |
| NPCE NeuroPace | Maintains: Overweight | $9 → $17 | $13.39 | +26.96% | 3 | Mar 12, 2024 | |
| SILK Silk Road Medical | Maintains: Neutral | $10 → $19 | $17.80 | +6.74% | 2 | Feb 29, 2024 | |
| RXST RxSight | Maintains: Overweight | $40 → $62 | $52.77 | +17.49% | 3 | Feb 29, 2024 | |
| PODD Insulet | Maintains: Overweight | $190 → $225 | $166.19 | +35.39% | 3 | Feb 23, 2024 | |
| PEN Penumbra | Downgrades: Neutral | $284 → $250 | $204.41 | +22.30% | 4 | Feb 23, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $115 → $125 | $119.35 | +4.73% | 3 | Feb 9, 2024 | |
| BAX Baxter International | Maintains: Neutral | $38 → $44 | $40.13 | +9.64% | 6 | Feb 9, 2024 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $31 → $36 | $14.69 | +145.06% | 4 | Jan 26, 2024 | |
| ZIMV ZimVie | Maintains: Neutral | $10 → $16 | $15.82 | +1.14% | 3 | Dec 20, 2023 | |
| INGN Inogen | Maintains: Underweight | $8 → $7 | $6.78 | +3.24% | 5 | Nov 8, 2023 | |
| NVRO Nevro | Maintains: Neutral | $23 → $18 | $11.32 | +59.01% | 4 | Nov 2, 2023 | |
| ATRC AtriCure | Maintains: Overweight | $60 → $50 | $23.17 | +115.80% | 2 | Nov 2, 2023 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $340 → $181 | $237.45 | -23.77% | 4 | Oct 17, 2023 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $100 | $86.43 | +15.70% | 2 | Jul 27, 2023 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $335 → $365 | $375.33 | -2.75% | 3 | Jul 21, 2023 | |
| IART Integra LifeSciences Holdings | Downgrades: Underweight | $56 → $43 | $28.34 | +51.73% | 4 | May 24, 2023 | |
| SYK Stryker | Maintains: Overweight | $285 → $315 | $335.61 | -6.14% | 3 | May 2, 2023 | |
| BLCO Bausch + Lomb | Maintains: Neutral | $15 → $17 | $14.79 | +14.94% | 2 | Feb 23, 2023 | |
| BVS Bioventus | Downgrades: Underweight | n/a | $3.98 | - | 2 | Nov 9, 2022 | |
| ABT Abbott Laboratories | Maintains: Overweight | $125 → $118 | $107.53 | +9.74% | 5 | Oct 20, 2022 | |
| UTRS Minerva Surgical | Downgrades: Underweight | n/a | $0.00 | - | 2 | Aug 10, 2022 | |
| IRTC iRhythm Technologies | Maintains: Overweight | $116 → $156 | $111.91 | +39.40% | 2 | Jan 27, 2022 | |
| MDT Medtronic | Downgrades: Neutral | n/a | $79.74 | - | 2 | Dec 17, 2021 | |
| AFIB Acutus Medical | Downgrades: Underweight | n/a | $0.17 | - | 2 | Nov 12, 2021 | |
| TMCI Treace Medical Concepts | Initiates: Overweight | n/a | $10.40 | - | 1 | May 18, 2021 | |
| GKOS Glaukos | Downgrades: Neutral | n/a | $99.48 | - | 1 | Feb 28, 2020 |
CONMED
Apr 25, 2024
Maintains: Overweight
Price Target: $115 → $75
Current: $65.78
Upside: +14.02%
Boston Scientific
Apr 25, 2024
Maintains: Overweight
Price Target: $72 → $82
Current: $73.17
Upside: +12.07%
The Cooper Companies
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $88.84
Upside: +35.07%
NeuroPace
Mar 12, 2024
Maintains: Overweight
Price Target: $9 → $17
Current: $13.39
Upside: +26.96%
Silk Road Medical
Feb 29, 2024
Maintains: Neutral
Price Target: $10 → $19
Current: $17.80
Upside: +6.74%
RxSight
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $52.77
Upside: +17.49%
Insulet
Feb 23, 2024
Maintains: Overweight
Price Target: $190 → $225
Current: $166.19
Upside: +35.39%
Penumbra
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $204.41
Upside: +22.30%
Zimmer Biomet Holdings
Feb 9, 2024
Maintains: Neutral
Price Target: $115 → $125
Current: $119.35
Upside: +4.73%
Baxter International
Feb 9, 2024
Maintains: Neutral
Price Target: $38 → $44
Current: $40.13
Upside: +9.64%
CVRx, Inc.
Jan 26, 2024
Maintains: Overweight
Price Target: $31 → $36
Current: $14.69
Upside: +145.06%
ZimVie
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $15.82
Upside: +1.14%
Inogen
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.78
Upside: +3.24%
Nevro
Nov 2, 2023
Maintains: Neutral
Price Target: $23 → $18
Current: $11.32
Upside: +59.01%
AtriCure
Nov 2, 2023
Maintains: Overweight
Price Target: $60 → $50
Current: $23.17
Upside: +115.80%
Inspire Medical Systems
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $237.45
Upside: -23.77%
Edwards Lifesciences
Jul 27, 2023
Maintains: Overweight
Price Target: $95 → $100
Current: $86.43
Upside: +15.70%
Intuitive Surgical
Jul 21, 2023
Maintains: Overweight
Price Target: $335 → $365
Current: $375.33
Upside: -2.75%
Integra LifeSciences Holdings
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $28.34
Upside: +51.73%
Stryker
May 2, 2023
Maintains: Overweight
Price Target: $285 → $315
Current: $335.61
Upside: -6.14%
Bausch + Lomb
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $14.79
Upside: +14.94%
Bioventus
Nov 9, 2022
Downgrades: Underweight
Price Target: n/a
Current: $3.98
Upside: -
Abbott Laboratories
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $107.53
Upside: +9.74%
Minerva Surgical
Aug 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.00
Upside: -
iRhythm Technologies
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $111.91
Upside: +39.40%
Medtronic
Dec 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $79.74
Upside: -
Acutus Medical
Nov 12, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.17
Upside: -
Treace Medical Concepts
May 18, 2021
Initiates: Overweight
Price Target: n/a
Current: $10.40
Upside: -
Glaukos
Feb 28, 2020
Downgrades: Neutral
Price Target: n/a
Current: $99.48
Upside: -